Tocilizumab administration in patients with SARS‐CoV‐2 infection: Subcutaneous injection vs intravenous infusion
Open Access
- 3 June 2020
- journal article
- letter
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (1) , 69-70
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Use of subcutaneous tocilizumab in patients with COVID‐19 pneumoniaJournal of Medical Virology, 2020
- Tocilizumab treatment in COVID‐19: A single center experienceJournal of Medical Virology, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Annals of the Rheumatic Diseases, 2016
- Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjectsInt. Journal of Clinical Pharmacology and Therapeutics, 2013
- Drug absorption, distribution, metabolism and excretion considerations in critically ill adultsExpert Opinion on Drug Metabolism & Toxicology, 2013